~~UNITED STATES~~ SECURITIES AND EXCHANGE COMMISSION ~~WASHINGTON, D.C. 20549~~

Washington, DC 20549

FORM 8-K

~~CURRENT~~Current ~~REPORT~~Report

~~PURSUANT~~Pursuant TOto ~~SECTION~~Section 13 ORor 15 (d) ~~OF THE SECURITIES EXCHANGE ACT OF 1934~~

~~DATE~~of OFthe ~~REPORT~~Securities ~~(DATE~~Exchange ~~OF EARLIEST EVENT REPORTED): February 28, 2019~~ Act

~~AEON~~September ~~GLOBAL~~25, ~~HEALTH CORP. (Exact name of registrant as specified in its charter)~~2019

~~COMMISSION~~Date ~~FILE~~of ~~NUMBER: 0-20190~~Report (Date of Earliest Event Reported)

DELAWARE	14-1673067
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

Aeon Global Health Corp.

~~2225 Centennial Drive Gainesville, GA 30504~~ (~~Address~~Exact ~~and~~name ~~zip~~of ~~code~~registrant ofas ~~principal~~specified ~~executive~~in ~~offices~~its charter)

1-(888) 661-0225 (Registrant’s telephone number, including area code

Delaware		000-20190		14-1673067
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification Number)

___________________________________________ (Former Name, if Changed Since Last Report)

2225 Centennial Drive
Gainesville, GA		30504
(Address of principal executive offices)		(Zip Code)

~~CHECK~~(888) ~~THE APPROPRIATE BOX BELOW IF THE FORM 8~~661-~~K FILING IS INTENDED TO SIMULTANEOUSLY SATISFY THE FILING OBLIGATION OF THE REGISTRANT UNDER ANY OF THE FOLLOWING PROVISIONS:~~ 0225

☐(Registrant's ~~Written~~telephone ~~communications~~number, ~~pursuant~~including toarea ~~Rule 425 under the Securities Act (17 CFR 230.425~~code)

☐Check ~~Soliciting~~the ~~material~~appropriate ~~pursuant~~box tobelow ~~Rule~~if ~~14a~~the Form 8-12K ~~under~~filing is intended to simultaneously satisfy the ~~Exchange~~filing ~~Act~~obligation ~~(17~~of ~~CFR~~the ~~240.14a-12)~~registrant under any of the following provisions:

☐[ ] ~~Pre-commencement~~Written communications pursuant to Rule ~~14d-2(b)~~425 under the ~~Exchange~~Securities Act (17 CFR ~~240~~230.~~14d-2(b~~425))

☐[ ] ~~Pre-commencement~~Soliciting ~~communications~~material pursuant to Rule ~~13e~~14a-~~4(c)~~12 under the Exchange Act (17 CFR 240.~~13e~~14a-~~4(c~~12))

~~Indicate~~[ ] byPre-commencement ~~check~~communications ~~mark~~pursuant ~~whether~~to ~~the registrant is an emerging growth company as defined in~~ Rule ~~405 of the Securities Act of 1933~~ 14d-2(~~17 CFR §230.405~~b) orunder ~~Rule 12b-2 of~~ the ~~Securities~~ Exchange Act ~~of 1934~~ (17 CFR §240.~~12b~~14d-2(b).)

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 31.0201 ~~Unregistered~~– ~~Sales~~Entry ofinto ~~Equity~~a ~~Securities.~~Material Definitive Agreement

AsOn ~~previously~~September ~~reported~~25, ~~on July 19~~2019, ~~2018, Aeon Global Health Corp. (~~the “Company”) entered into a ~~Settlement~~debt ~~and~~conversion ~~Restructuring~~agreement ~~Agreement (the “Agreement”)~~ with ~~Peachstate~~Optimum ~~Health~~Ventures ~~Management,~~and ~~LLC~~Hanif ~~(“Peachstate”)~~Roshan, ~~its wholly-owned subsidiary, and~~ the ~~former~~holders ~~members~~ of ~~Peachstate~~a ~~included~~total inof ~~the Agreement (the “Former Members”)~~$3,289,315 ~~including~~in ~~its chief executive officer~~debt. Pursuant to ~~the~~this ~~Agreement~~agreement, the ~~parties~~Company ~~agreed~~will ~~to,~~convert ~~among~~up ~~other~~to ~~things~~$3,289,315 ~~resolve~~in ~~certain~~promissory ~~disagreements~~notes ~~among~~and ~~themselves~~other ~~relating~~debt toheld ~~the~~by ~~interpretation~~these oftwo ~~certain~~parties ~~provisions~~into ofcommon ~~the~~shares ~~Amended and Restated Agreement and Plan~~ of ~~Merger dated as of January 26, 2016, and as subsequently amended (~~the ~~“Merger~~Company ~~Agreement”)~~at ~~pursuant to which Peachstate became~~ a ~~wholly-owned~~rate ~~subsidiary~~ of ~~the Company (the “Merger”)~~$0.105 Aper ~~detailed~~share, ~~summary~~resulting ofin the ~~terms~~issuance ~~and conditions~~ of ~~the~~up ~~Agreement~~to ~~was initially reported by the Company in a Current Report on Form 8-K filed on July 24~~31,326,809 ~~2018~~common shares.

~~Under~~These the Agreement, the Company agreed that in consideration of the agreements by the Former Members set forth therein, including the restructuring of the consideration due to them under the Merger Agreement, it shall issue an aggregate of 2,500,000 shares ofwill ~~its Common Stock to the Former Members. Such additional shares shall~~ be issued tounder the ~~Former~~exemption ~~Members~~granted ~~pro~~by ~~rata~~Section ~~based~~4(a)(2) ~~on their respective percentage ownership~~ of ~~Peachstate prior to~~ the ~~Merger~~Securities ~~and shall be deemed earned and issued on February 28, 2019~~Act. On February 28, 2019, the Company issued the Former Members the additional shares of Common Stock contemplated by the Agreement. Following such issuance, there are 9,915,064 shares of Common Stock outstanding.

~~The~~Item issuances of the shares pursuant to the Agreement have been determined to be exempt from registration under the Securities Act of 1933, in reliance on Section 4(a)(2) thereof, as transactions by an issuer not involving a public offering, in which the investors are accredited and have acquired the securities for investment purposes and not with a view to or for sale in connection with any distribution thereof3.02 ~~These~~– ~~securities~~Unregistered ~~have~~Sales not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This disclosure does not constitute an offer to sell or the solicitation of anEquity offer to buy any of the Company’s securities, nor will there be any sales of these securities by the Company in any state or jurisdiction in which the offer, solicitation or sale would be unlawful. The foregoing summary of the Agreement is qualified in its entirety by reference to the full text of the Agreement, a copy of which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 24, 2018, and which is incorporated herein by reference.Securities

2See Item 1.01 above.

~~SIGNATURE~~Item 9.01 – Exhibits

~~Pursuant~~Exhibit to10.1 ~~the~~– ~~requirements~~Conversion ofagreement ~~the~~dated ~~Securities~~September ~~Exchange Act of 1934~~25, ~~the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.~~2019

	AEON GLOBAL HEALTH CORP.
	By: /s/ Hanif A. Roshan
	Name: Hanif A. Roshan
	Title: Chief Executive Officer
Date: March 4, 2019

SIGNATURES

3Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Aeon Global Health Corp.

By:	/s/ Hanif A. Roshan
	Hanif A. Roshan
	Chief Executive Officer

Dated: October 1, 2019

Filing Compare · Aeon Global Health Corp.